Dataset Information

Renal artery sympathetic denervation: observations from the UK experience.

ABSTRACT:

Background

Renal denervation (RDN) may lower blood pressure (BP); however, it is unclear whether medication changes may be confounding results. Furthermore, limited data exist on pattern of ambulatory blood pressure (ABP) response-particularly in those prescribed aldosterone antagonists at the time of RDN.

Methods

We examined all patients treated with RDN for treatment-resistant hypertension in 18 UK centres.

Results

Results from 253 patients treated with five technologies are shown. Pre-procedural mean office BP (OBP) was 185/102 mmHg (SD 26/19; n = 253) and mean daytime ABP was 170/98 mmHg (SD 22/16; n = 186). Median number of antihypertensive drugs was 5.0: 96 % ACEi/ARB; 86 % thiazide/loop diuretic and 55 % aldosterone antagonist. OBP, available in 90 % at 11 months follow-up, was 163/93 mmHg (reduction of 22/9 mmHg). ABP, available in 70 % at 8.5 months follow-up, was 158/91 mmHg (fall of 12/7 mmHg). Mean drug changes post RDN were: 0.36 drugs added, 0.91 withdrawn. Dose changes appeared neutral. Quartile analysis by starting ABP showed mean reductions in systolic ABP after RDN of: 0.4; 6.5; 14.5 and 22.1 mmHg, respectively (p < 0.001 for trend). Use of aldosterone antagonist did not predict response (p > 0.2).

Conclusion

In 253 patients treated with RDN, office BP fell by 22/9 mmHg. Ambulatory BP fell by 12/7 mmHg, though little response was seen in the lowermost quartile of starting blood pressure. Fall in BP was not explained by medication changes and aldosterone antagonist use did not affect response.

SUBMITTER: Sharp AS

PROVIDER: S-EPMC4882343 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Renal artery sympathetic denervation: observations from the UK experience.

Sharp Andrew S P AS Davies Justin E JE Lobo Melvin D MD Bent Clare L CL Mark Patrick B PB Burchell Amy E AE Thackray Simon D SD Martin Una U McKane William S WS Gerber Robert T RT Wilkinson James R JR Antonios Tarek F TF Doulton Timothy W TW Patterson Tiffany T Clifford Piers C PC Lindsay Alistair A Houston Graeme J GJ Freedman Jonathan J Das Neelan N Belli Anna M AM Faris Mohamad M Cleveland Trevor J TJ Nightingale Angus K AK Hameed Awais A Mahadevan Kalaivani K Finegold Judith A JA Mather Adam N AN Levy Terry T D'Souza Richard R Riley Peter P Moss Jonathan G JG Di Mario Carlo C Redwood Simon R SR Baumbach Andreas A Caulfield Mark J MJ Dasgupta Indranil I

Clinical research in cardiology : official journal of the German Cardiac Society 20160122 6

<h4>Background</h4>Renal denervation (RDN) may lower blood pressure (BP); however, it is unclear whether medication changes may be confounding results. Furthermore, limited data exist on pattern of ambulatory blood pressure (ABP) response-particularly in those prescribed aldosterone antagonists at the time of RDN.<h4>Methods</h4>We examined all patients treated with RDN for treatment-resistant hypertension in 18 UK centres.<h4>Results</h4>Results from 253 patients treated with five technologies ...[more]

PMID: 26802018

Similar Datasets

Project description:The aim of the present study was to determine if renal sympathetic denervation (RSD) may alleviate isoproterenol-induced left ventricle remodeling, and to identify the underlying mechanism. A total of 70 rats were randomly divided into control (n=15), sham operation (n=15), heart failure (HF) with sham operation (HF + sham; n=20) and HF with treatment (HF + RSD; n=20) groups. The HF model was established by subcutaneous injection of isoproterenol; six weeks later, 1eft ventricular internal diameter at end?systole (LVIDs), left ventricular systolic posterior wall thickness (LVPWs), 1eft ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) were measured. Plasma norepinephrine (NE), angiotensin II (Ang II) and aldosterone (ALD) levels were measured by ELISA. Myocardial collagen volume fraction (CVF) was determined by Masson's staining. Reverse transcription?quantitative polymerase chain reaction was used to determine the mRNA expression levels of ventricular transforming growth factor?? (TGF??), connective tissue growth factor (CTGF) and microRNAs (miRs), including miR?29b, miR?30c and miR?133a. The results demonstrated that LVIDs and LVPWs in the HF + RSD group were significantly decreased compared with the HF + sham group. By contrast, LVFS and LVEF in the HF + RSD group were significantly increased compared with the HF + sham group. RSD significantly reduced the levels of plasma NE, Ang II and ALD. CVF in the HF + RSD group was reduced by 38.1% compared with the HF + sham group. Expression levels of TGF?? and CTGF were decreased, whereas those of miR?29b, miR?30c and miR?133a were increased, in the HF + RSD group compared with the HF + sham group. These results indicated that RSD alleviates isoproterenol?induced left ventricle remodeling potentially via downregulation of TGF??/CTGF and upregulation of miR?29b, miR?30c and miR?133a. RSD may therefore be an effective non?drug therapy for the treatment of heart failure.

Dataset Information

Renal artery sympathetic denervation: observations from the UK experience.

Background

Methods

Results

Conclusion

Publications

Renal artery sympathetic denervation: observations from the UK experience.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets